North American Prodromal Synucleinopathy Consortium

NCT03623672 · tracked via the Priya Life Science Canada tracker

Sponsor

Washington University School of Medicine

Phase

Observational

Started

2018-08-29

Last updated

2024-11-06

Condition(s) studied

REM Sleep Behavior DisorderParkinson DiseaseLewy Body DiseaseDementia With Lewy BodiesMultiple System AtrophyREM Sleep Parasomnias

Study summary

This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Idiopathic REM sleep behavior disorder Exclusion Criteria: * REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia, Parkinson's Disease, etc) * Other neurological disorder

Primary outcome measure(s)

Prodromal Synucleinopathy Rating Scale — 2 years
Rating scale combining neurocognitive battery, motor, autonomic, olfaction, color vision functions. Global score range 0-3, with higher score indicating greater symptoms of synucleinopathy.

Trial sites (10)

Facility	City	Region
Banner Sun Health Research Institute	Sun City	Arizona
University of California Los Angeles	Los Angeles	California
Stanford University	Redwood City	California
Emory University	Atlanta	Georgia
Massachusetts General Hospital	Boston	Massachusetts
University of Minnesota	Minneapolis	Minnesota
Mayo Clinic	Rochester	Minnesota
Washington University	St Louis	Missouri
Portland VA Medical Center	Portland	Oregon
McGill University	Montreal	Quebec

More Washington University School of Medicine trials in Canada

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Active, not recruiting

Spinraza in Adult Spinal Muscular Atrophy Active, not recruiting

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Active, not recruiting

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases Recruiting

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer Active, not recruiting

Other trials for the same condition

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort Recruiting

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease Active, not recruiting

Exercise to Improve Sleep in Parkinson's Disease Recruiting

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia Starting soon

Brain-Machine Interface for Freezing of Gait Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03623672 on ClinicalTrials.gov ↗ ← All trials in Canada